JPMorgan Chase & Co. Buys 33,150 Shares of ChromaDex Co. (NASDAQ:CDXC)

JPMorgan Chase & Co. boosted its stake in ChromaDex Co. (NASDAQ:CDXC) by 11.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331,916 shares of the company’s stock after acquiring an additional 33,150 shares during the period. JPMorgan Chase & Co. owned 0.43% of ChromaDex worth $1,211,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company acquired a new position in shares of ChromaDex in the 2nd quarter valued at about $31,000. FMR LLC acquired a new position in ChromaDex in the third quarter valued at approximately $55,000. Marshall Wace LLP bought a new position in shares of ChromaDex during the 2nd quarter worth approximately $56,000. SG Americas Securities LLC acquired a new stake in shares of ChromaDex during the 3rd quarter worth approximately $61,000. Finally, MetLife Investment Management LLC increased its stake in shares of ChromaDex by 39.3% in the 3rd quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock valued at $66,000 after acquiring an additional 5,115 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Analysts Set New Price Targets

CDXC has been the topic of several recent research reports. HC Wainwright increased their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 15th. Finally, Roth Mkm boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

ChromaDex Price Performance

Shares of CDXC opened at $5.95 on Friday. ChromaDex Co. has a 1 year low of $1.45 and a 1 year high of $7.97. The stock’s fifty day moving average price is $6.23 and its two-hundred day moving average price is $4.56. The firm has a market cap of $454.48 million, a PE ratio of 595.60 and a beta of 2.21.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The business had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the previous year, the business earned ($0.01) EPS. Sell-side analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.64% of the stock is currently owned by company insiders.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.